FOLLOWUS
Effect of Jieze No.1 (洁泽 号) on cervicitis caused by ureaplasma urealyticum and on ureaplasma urealyticum in vitro
- Chinese Journal of Integrative Medicine Vol. 14, Issue 2, Pages: 88-93(2008)
- Affiliations：
Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology,Wuhan,China
- Author bio：
- Funds：Supported by the 10th Five-Year National Science and Technology Project (No.2004BA709B13-02)
DOI：10.1007/s11655-008-0088-2
CLC：Published：2008，
Published Online：6 August 2008，
Scan for full text
Wei, H., Chen, Z., Xu, P. et al. Effect of Jieze No.1 (洁泽 号) on cervicitis caused by ureaplasma urealyticum and on ureaplasma urealyticum in vitro, ., Chin. J. Integr. Med. 14, 88–93 (2008). https://doi.org/10.1007/s11655-008-0088-2
Hong Wei, Zhuo Chen, Ping Xu, et al. Effect of Jieze No.1 (洁泽 号) on cervicitis caused by ureaplasma urealyticum and on ureaplasma urealyticum in vitro. [J]. Chinese Journal of Integrative Medicine 14(2):88-93(2008)
Wei, H., Chen, Z., Xu, P. et al. Effect of Jieze No.1 (洁泽 号) on cervicitis caused by ureaplasma urealyticum and on ureaplasma urealyticum in vitro, ., Chin. J. Integr. Med. 14, 88–93 (2008). https://doi.org/10.1007/s11655-008-0088-2 DOI：
Hong Wei, Zhuo Chen, Ping Xu, et al. Effect of Jieze No.1 (洁泽 号) on cervicitis caused by ureaplasma urealyticum and on ureaplasma urealyticum in vitro. [J]. Chinese Journal of Integrative Medicine 14(2):88-93(2008) DOI： 10.1007/s11655-008-0088-2.
摘要
To observe the clinical therapeutic effect of Jieze No. 1 (洁泽 I 号) on cervicitis caused by ureaplasma urealyticum and its inhibitory effect on ureaplasma urealyticum (Uu) in vitro. A total of 393 patients suffering from cervicitis induced by ureaplasma urealyticum without other complications were randomly assigned to 3 groups
the combined treatment group: 140 patients treated with Chinese herbs Jieze No.1 by vaginal lavage
30 min each time
once a day for 10 consecutive days and oral administration of Azithromycin
1.0 g once every 72 h for three times; Jieze group: 115 patients were treated with Jieze No.1 alone by vaginal lavage
30 min each time
once a day for 10 consecutive days; and the Azithromycin group: 138 patients were treated with oral administration of Azithromycin
1.0 g once in 72 h for three times. All the patients were treated for 1 therapeutic course and condom were used for contraception during the treatment course. The Uu patients were examined again after 21 days of treatment. The therapeutic effect on cervicitis was observed. The experimental study of Jieze No. 1 on the Uu strain separated from the secretion of the urogenital tract was also observed. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the Uu were investigated. The total effective rate of the combined group was 85.3%
showing a significant difference compared with the Jieze group (67.8%) and the Azithromycin group (60.3%
both P<0.01). There was no statistical significance between the latter two groups (P>0.05). The clearing rate of Uu in the combined group was 78.4%
that of the Jieze group was 60.9% and the Azithromycin group was 47.9%. The combined group also showed a significant difference in comparison with the other two groups (all P<0.01). Especially for the drug-resistant strain
the clearing rate of Uu reached 48.1% in the combined group
42.1% in the Jieze group
and 16.1% in the Azithromycin group
respectively. The clearing rate of Uu for the drug-resistant strain in the former two groups had significant differences in comparison with the latter (P<0.01
P<0.05)
while there was no significant difference between the former two (P>0.05). The range of MIC and MBC of Jieze No. 1 to the drug-resistant strain of Uu was 15.62–250.00 mg/mL. To the non-drug-resistant MIC and MBC strain
it was 15.62–125.00 mg/mL. For the drug-resistant strain
MIC50 was ⩽ 31.25 mg/mL
MBC50 was ⩽ 62.50 mg/mL
MIC90 was ⩽ 125.00 mg/mL and MBC90 was 250.00 mg/mL. For the non-drug-resistant strain
MIC50 was ⩽ 31.25 mg/mL
MBC50 was ⩽ 62.50 mg/mL
MIC90 was ⩽ 62.50 mg/mL and MBC90 was ⩽ 125.00 mg/mL. Jieze No.1 combined with Azithromycin can effectively treat cervicitis caused by Uu. The laboratory study confirms that Jieze No. 1 has an inhibitory effect on ureaplasma urealyticum strain. It has a remarkably effective therapeutic effects on drug-resistant strains
which is worthy of further research.
Abstract
To observe the clinical therapeutic effect of Jieze No. 1 (洁泽 I 号) on cervicitis caused by ureaplasma urealyticum and its inhibitory effect on ureaplasma urealyticum (Uu) in vitro. A total of 393 patients suffering from cervicitis induced by ureaplasma urealyticum without other complications were randomly assigned to 3 groups
the combined treatment group: 140 patients treated with Chinese herbs Jieze No.1 by vaginal lavage
30 min each time
once a day for 10 consecutive days and oral administration of Azithromycin
1.0 g once every 72 h for three times; Jieze group: 115 patients were treated with Jieze No.1 alone by vaginal lavage
30 min each time
once a day for 10 consecutive days; and the Azithromycin group: 138 patients were treated with oral administration of Azithromycin
1.0 g once in 72 h for three times. All the patients were treated for 1 therapeutic course and condom were used for contraception during the treatment course. The Uu patients were examined again after 21 days of treatment. The therapeutic effect on cervicitis was observed. The experimental study of Jieze No. 1 on the Uu strain separated from the secretion of the urogenital tract was also observed. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the Uu were investigated. The total effective rate of the combined group was 85.3%
showing a significant difference compared with the Jieze group (67.8%) and the Azithromycin group (60.3%
both P<0.01). There was no statistical significance between the latter two groups (P>0.05). The clearing rate of Uu in the combined group was 78.4%
that of the Jieze group was 60.9% and the Azithromycin group was 47.9%. The combined group also showed a significant difference in comparison with the other two groups (all P<0.01). Especially for the drug-resistant strain
the clearing rate of Uu reached 48.1% in the combined group
42.1% in the Jieze group
and 16.1% in the Azithromycin group
respectively. The clearing rate of Uu for the drug-resistant strain in the former two groups had significant differences in comparison with the latter (P<0.01
P<0.05)
while there was no significant difference between the former two (P>0.05). The range of MIC and MBC of Jieze No. 1 to the drug-resistant strain of Uu was 15.62–250.00 mg/mL. To the non-drug-resistant MIC and MBC strain
it was 15.62–125.00 mg/mL. For the drug-resistant strain
MIC50 was ⩽ 31.25 mg/mL
MBC50 was ⩽ 62.50 mg/mL
MIC90 was ⩽ 125.00 mg/mL and MBC90 was 250.00 mg/mL. For the non-drug-resistant strain
MIC50 was ⩽ 31.25 mg/mL
MBC50 was ⩽ 62.50 mg/mL
MIC90 was ⩽ 62.50 mg/mL and MBC90 was ⩽ 125.00 mg/mL. Jieze No.1 combined with Azithromycin can effectively treat cervicitis caused by Uu. The laboratory study confirms that Jieze No. 1 has an inhibitory effect on ureaplasma urealyticum strain. It has a remarkably effective therapeutic effects on drug-resistant strains
which is worthy of further research.
关键词
Jieze No.1ureaplasma urealyticumcervicitis
Keywords
Jieze No.1ureaplasma urealyticumcervicitis
references
Xiao R, Wen HQ, Cao CH, et al. Mycoplasma infection survey and drug sensitive analysis of patients in STD clinics of Hunan district in 2002. J Clin Dermatol (Chin) 2003;32(8):451–452.
Zhang LM, Zhang XM, Sun Y, et al. Sensitive analysis of ureaplasma urealyticum in 283 patients with nongonococcal urethritis (cervicitis). J Clin Dermatol (Chin) 2003;32(8):455–466.
Le J, ed. Gynecology. 6th ed. Beijing: People’s Medical Publishing House, 2003:381.
Ministry of Health of P. R. China. Guiding principle of clinical research on new drugs of TCM. 1993:250–255.
Disease Control Department of Ministry of Health of P. R. China. Handbook of sexually transmitted diseases treatment. Nanjing: Jiangsu Press of Science and Technology, 1990:96–98.
Zou XB, Zhang GW, Yan GF, et al. To introduce one kind of home-made ureaplasma urealyticum culture medium. Chin J Dermatovenerol (Chin) 1996;10(1):454–455.
Robertson JA, Stemke GW. Expanded serotyping scheme for ureaplasma urealyticum strains isolated from humans. J Clin Microbiol 1982;15:873–875.
Weng ZS. Sensibility research of ureaplasma urealyticum on 12 medicines in vitro. J Clin Dermatol (Chin) 1999;28(1):21–22.
Wang YH, Cheng JJ, Chen BM, et al. Determination of Azithromycin in human plasma by HPLC-MS and its relative bioavailability. Chin Pharm J (Chin) 2006;41(1):51–54.
Liu Q, Lu C. Research progress of pathogenicity of Uu in female subgenital tract. Foreign Med Sci: Sect Dermatol Venereol (Chin) 2005;31(5):326–327.
Fu ZY, Li WY, Gao QX, et al. The clinical efficacy of moxifloxacin in treating patients with non-gonococcal urethritis (cervicitis). Chin J Human Sexuality (Chin) 2004;13(12):3–5.
0
Views
368
Downloads
5
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
